

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 April 2009 (02.04.2009)

PCT

(10) International Publication Number  
**WO 2009/039966 A3**

(51) International Patent Classification:

*A61K 38/17* (2006.01)    *A61P 25/28* (2006.01)  
*A61K 38/08* (2006.01)    *A61P 31/00* (2006.01)  
*A61P 31/20* (2006.01)    *A61P 35/00* (2006.01)  
*A61P 3/00* (2006.01)    *A61P 37/00* (2006.01)  
*A61P 9/00* (2006.01)    *A61P 31/18* (2006.01)  
*A61P 11/00* (2006.01)    *A61P 31/06* (2006.01)

(21) International Application Number:

PCT/EP2008/007500

(22) International Filing Date:

9 September 2008 (09.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07017754.8 11 September 2007 (11.09.2007) EP

(71) Applicant (for all designated States except US): **MONDOBIOTECH LABORATORIES AG** [LI/LI]; Herrens-gasse 21, FL-9490 Vaduz (LI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEVEC, Dorian** [DE/DE]; Kriegerstrasse 62, 82110 Germering (DE). **CAVALLI, Fabio** [CH/CH]; Via Pasquée 23, CH-6925 Gentilino (CH). **CAVALLI, Vera** [CH/CH]; Via Pasquée, 23, CH-6925 Gentilino (CH). **BACHER, Ger-ald** [DE/DE]; Masurenweg 5, 82110 Germering (DE).

(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys, Jasminweg 9, 14052 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

17 December 2009

(54) Title: USE OF NF-KAPPAB INHIBITOR SN50 AND OPTIONALLY ANGIOTENSIN III AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG HBV INFECTION

(57) Abstract: The present invention is directed to the use of the peptide compound Ala-Ala-Val-Ala- Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu- Met-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious dis-eases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu- Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.



WO 2009/039966 A3

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2008/007500

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K38/08 A61P31/18 A61P31/06 A61P3/00 A61P9/00  
A61P11/00 A61P25/28 A61P31/00 A61P35/00 A61P37/00  
A61P31/20 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	IGIC RAJKO ET AL: "Properties and distribution of angiotensin I converting enzyme." CURRENT PHARMACEUTICAL DESIGN, vol. 9, no. 9, 2003, pages 697-706, XP009121266 ISSN: 1381-6128 the whole document	1-15
A	HAULICA I ET AL: "New bioactive angiotensins formation pathways and functional involvements." ROMANIAN JOURNAL OF INTERNAL MEDICINE = REVUE ROUMAINE DE MÉDECINE INTERNE 2004, vol. 42, no. 1, 2004, pages 27-40, XP009121336 ISSN: 1220-4749 the whole document	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

20 August 2009

Date of mailing of the international search report

27/10/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Hars, Jesko

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RUIZ-ORTEGA M ET AL: "PROINFLAMMATORY ACTIONS OF ANGIOTENSINS" CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, RAPID SCIENCE, LONDON, GB, vol. 10, no. 3, 1 May 2001 (2001-05-01), pages 321-329, XP009083081 ISSN: 1062-4821 the whole document	1-15
A	US 5 629 292 A (RODGERS KATHLEEN E [US] ET AL) 13 May 1997 (1997-05-13) the whole document	1-15
A	HEFFELFINGER S C: "The renin angiotensin system in the regulation of angiogenesis" CURRENT PHARMACEUTICAL DESIGN, vol. 13, no. 12, April 2007 (2007-04), pages 1215-1229, XP002541993 ISSN: 1381-6128 the whole document	1-15
P,A	AGER ELEANOR I ET AL: "The renin-angiotensin system and malignancy" CARCINOGENESIS (OXFORD), vol. 29, no. 9, 16 July 2008 (2008-07-16), pages 1675-1684, XP002541994 ISSN: 0143-3334 the whole document	1-15
A	US 6 239 109 B1 (RODGERS KATHLEEN E [US] ET AL) 29 May 2001 (2001-05-29) the whole document	1-15
A	DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06), TAKEMOTO YUJI ET AL: "Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis" XP002542007 Database accession no. PREV199800357237 abstract & THORAX, vol. 53, no. 6, June 1998 (1998-06), pages 459-462, ISSN: 0040-6376	1-15
-/--		

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE MEDLINE [Online]  US NATIONAL LIBRARY OF MEDICINE (NLM),  BETHESDA, MD, US; 2002,  DITIATKOV A E ET AL: "[Respiratory and  renal functions and blood electrolytic  composition in patients with pulmonary  tuberculosis in the treatment of heart  failure]"  XP002542008  Database accession no. NLM12125252  abstract  &amp; PROBLEMY TUBERKULEZA 2002, no. 4, 2002,  pages 39-41,  ISSN: 0032-9533</p>	1-15
P,A	<p>LI XIAOPENG ET AL: "Angiotensin  converting enzyme-2 is protective but  downregulated in human and experimental  lung fibrosis"  AMERICAN JOURNAL OF PHYSIOLOGY - LUNG  CELLULAR AND MOLECULAR PHYSIOLOGY,  vol. 295, no. 1,  25 April 2008 (2008-04-25), pages  L178-L185, XP002541995  ISSN: 1040-0605  the whole document</p>	1-15
A	<p>UHAL BRUCE D ET AL: "Angiotensin-TGF-beta  1 crosstalk in human idiopathic pulmonary  fibrosis: Autocrine mechanisms in  myofibroblasts and macrophages"  CURRENT PHARMACEUTICAL DESIGN,  vol. 13, no. 12, April 2007 (2007-04),  pages 1247-1256, XP009121584  ISSN: 1381-6128  the whole document</p>	1-15
A	<p>DATABASE EMBASE [Online]  ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,  NL; November 2003 (2003-11),  WOO D S ET AL: "The Therapeutic Effect of  Angiotensin II Receptor Antagonist in  Idiopathic Pulmonary Fibrosis"  XP002542009  Database accession no. EMB-2004055454  abstract  &amp; TUBERCULOSIS AND RESPIRATORY DISEASES  200311 KR,  vol. 55, no. 5, November 2003 (2003-11),  pages 478-487,  ISSN: 0378-0066</p>	1-15
	----- -/--	

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MOLTENI AGOSTINO ET AL: "Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis"</p> <p>CURRENT PHARMACEUTICAL DESIGN, vol. 13, no. 13, May 2007 (2007-05), pages 1307-1316, XP002541996 ISSN: 1381-6128 the whole document</p> <p>-----</p>	1-15
A	<p>XIAO FAN ET AL: "Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B"</p> <p>JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 21, no. 9, September 2006 (2006-09), pages 1488-1491, XP002541997 ISSN: 0815-9319 the whole document</p> <p>-----</p>	1-15
A	<p>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, LIU Z ET AL: "THE RELATIONSHIP BETWEEN HEPATITIS B AND RENIN ANGIOTENSIN ALDOSTERONE SYSTEM"</p> <p>XP002542010 Database accession no. PREV199293069186 abstract &amp; JOURNAL OF WEST CHINA UNIVERSITY OF MEDICAL SCIENCES, vol. 22, no. 3, 1991, pages 303-306, ISSN: 0257-7712</p> <p>-----</p>	1-15
A	<p>ROCKEY ET AL: "Antifibrotic therapy in chronic liver disease"</p> <p>CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 3, no. 2, 1 February 2005 (2005-02-01), pages 95-107, XP005120678 ISSN: 1542-3565 the whole document</p> <p>-----</p>	1-15

-/--

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MIECZYSLAW LITWIN ET AL: "Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors" PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, vol. 21, no. 11, 15 August 2006 (2006-08-15), pages 1716-1722, XP019428889 ISSN: 1432-198X the whole document</p>	1-15
A	<p>THEUER JUERGEN ET AL: "Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats" BMC CARDIOVASCULAR DISORDERS, BIOMED CENTRAL, LONDON, GB, vol. 2, no. 1, 18 January 2002 (2002-01-18), page 3, XP021015221 ISSN: 1471-2261 the whole document</p>	1-15
A	<p>PENN H ET AL: "Scleroderma renal crisis: patient characteristics and long-term outcomes" QJM, vol. 100, no. 8, August 2007 (2007-08), pages 485-494, XP002541998 ISSN: 1460-2725 the whole document</p>	1-15
A	<p>DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 September 2001 (2001-09-01), QUALI N: "[Complications in kidney transplantation]" XP002542011 Database accession no. NLM11577577 abstract &amp; PRESSE MÉDICALE (PARIS, FRANCE : 1983) 1 SEP 2001, vol. 30, no. 24 Pt 2, 1 September 2001 (2001-09-01), pages 13-15, ISSN: 0755-4982</p>	1-15

-/--

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HIRAMATSU NORIYUKI ET AL: "Angiotensin II type I receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model"</p> <p>JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 18, no. 2, February 2007 (2007-02), pages 515-527, XP002541999 ISSN: 1046-6673 the whole document</p>	1-15
A	<p>IDEURA HIROSHI ET AL: "Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy"</p> <p>AMERICAN JOURNAL OF PHYSIOLOGY - RENAL PHYSIOLOGY, vol. 293, no. 4, 25 July 2007 (2007-07-25), pages F1214-F1221, XP002542000 ISSN: 0363-6127 the whole document</p>	1-15
A	<p>HYLAND L J ET AL: "Adaptation of the plasma renin radioimmunoassay for use with HIV-1 protease"</p> <p>ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 197, no. 1, 15 August 1991 (1991-08-15), pages 225-230, XP024823696 ISSN: 0003-2697 [retrieved on 1991-08-15] the whole document</p>	1-15
X	<p>D'ACQUISTO F ET AL: "From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors"</p> <p>CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 6, no. 4, 1 August 2006 (2006-08-01), pages 387-392, XP025229682 ISSN: 1471-4892 [retrieved on 2006-08-01] the whole document</p>	1,6-15
X	<p>SATO Y ET AL: "Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappa B"</p> <p>GUT, vol. 55, no. 12, December 2006 (2006-12), pages 1801-1808, XP009121683 ISSN: 0017-5749 the whole document</p>	1,6-15

-/--

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2008/007500

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/37821 A (UNIV VANDERBILT [US]; HAWIGER JACK J [US]; ROBINSON DANIEL [US]; VEACH) 31 May 2001 (2001-05-31) page 21, paragraph 2 -----	1,6-15



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/007500

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5629292	A	13-05-1997	AT 210677 T 15-12-2001
			AU 706333 B2 17-06-1999
			AU 7730294 A 10-04-1995
			CA 2172493 A1 30-03-1995
			DE 69429450 D1 24-01-2002
			DE 69429450 T2 25-07-2002
			DK 730465 T3 08-04-2002
			EP 0730465 A1 11-09-1996
			ES 2168312 T3 16-06-2002
			JP 9502977 T 25-03-1997
			PT 730465 E 28-06-2002
			WO 9508337 A1 30-03-1995
			ZA 9407338 A 10-05-1995
			<hr style="border-top: 1px dashed black;"/>
US 6239109	B1	29-05-2001	US 7288522 B1 30-10-2007
			US 2009062210 A1 05-03-2009
<hr style="border-top: 1px dashed black;"/>			
WO 0137821	A	31-05-2001	AT 334664 T 15-08-2006
			AU 783479 B2 03-11-2005
			AU 1933101 A 04-06-2001
			BR 0015977 A 06-06-2006
			CA 2391943 A1 31-05-2001
			DE 60029829 T2 01-03-2007
			EP 1246616 A1 09-10-2002
			JP 2003514852 T 22-04-2003